PUBLISHER: FirstWord Group | PRODUCT CODE: 1366646
PUBLISHER: FirstWord Group | PRODUCT CODE: 1366646
Why are trials of Merck & Co's Keytruda+Moderna's personalised cancer vaccine mRNA-4157 generating particular interest amongst opinion leaders? What underpins experts' excitement about Iovance's tumour-infiltrating lymphocyte therapy Contego, and what factors do they say may limit its uptake? Do oncologists see a wider role in melanoma therapy for Immunocore/Medison Pharma's bispecific Kimmtrak? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to KOL Bulletins.